SJ , - you are right , expectation should be lower

SJ , - you are right , expectation should be lower , it is always better to be pleasantly surprise ...)

480 mil estimate was done predicting 20,000 patients in the first year and price of 24,000.00 per patients per year.

With the new price of 70,000.00 per patient per year ( and now they even talking 110,000.00 )
That will give us less than 7000 patients for the first year.

IMO , such a low number is not possible ...

They predicting for 2020 over 260 K patients with MDR2 , this will be about
180,000 patients CCR5 positive .
They predicting about 25,000 patients with MDR 3 , this will be about 17.500 patients CCR5 positive.

If those will be my patients all MDR2 I will put on Leronlimab so they don't progress to MDR3.
MDR3 people are much sicker already...

And for MDR 3 they have only Maraviroc and IV Ibalizumab ..
I will think most of this over 17,500 patients will like to try SC Leronlimab...

So whichever way we looking , 480 M is extremely conservative.

As for insurance diagnosis code I am not sure if it is different for resistant HIV with not resistant , I don't think so . I know when patient has AIDS code is different.

Anyway my first cousin is a surgeon , very often operating in the hospital , I just called and left him a message to call me back, and at any time if he see infectious disease to ask this Q.
I also will ask my best friend who is practicing internist in NJ the same Q , she should really know the answer.
I will do that this evening , now she has office hrs...

I will let you know the answer ...